Stellar Business Award

Tosk, Inc. Wins Best Pharmaceutical Discovery and Development in Global

Tosk, Inc. logo: Brian Frenzel

Why Tosk, Inc. Was Selected as the Winner

After careful review, we have selected Tosk, Inc. and its founder, Brian Frenzel, as the recipients of this year’s Stellar Business Award. Tosk’s innovative approach to cancer treatment, particularly their development of drugs that prevent the adverse side effects of cancer therapies, is groundbreaking. Their patented side-effect-blocking agents, TK-90 and TK-39, have shown promising results in clinical studies, demonstrating both safety and efficacy. Furthermore, their work on oncogenic KRAS-inhibiting drug candidates, sponsored by NIH SBIR grants, has the potential to significantly impact the treatment of various cancers. Mr. Frenzel’s extensive experience in the life science industry, his entrepreneurial spirit, and his proven track record of success in founding and leading multiple companies to acquisition, make him an exemplary leader in the field. Tosk, Inc.’s innovative contributions to cancer treatment and Mr. Frenzel’s leadership make them a clear choice for this award.

They displayed all of the qualities that we at Stellar Business look for when determining excellence. These qualities include outstanding growth, service to their community, and excellent business practices. We determined that they excel in these criteria as the top Pharmaceutical Discovery and Development in Global.

About Tosk, Inc.

Tosk discovers and develops new drugs to selectively prevent the adverse side effects of widely used cancer therapies and to block the activity of cancer genes that drive tumor growth.

Tosk has developed and patented two important side-effect-blocking agents, TK-90 for mucositis and pulmonary fibrosis, and TK-39 for cardiotoxicity. TK-90 has completed “proof of concept” in Phase 2a clinical studies demonstrating safety and efficacy in head and neck cancer patients and has applications outside of cancer. A third lead compound, TK-88, has been discovered for chemotherapy nephrotoxicity side-effect-prevention. Sponsored by NIH SBIR grants, Tosk has also identified oncogenic KRAS-inhibiting drug candidates. These are being developed to treat KRAS-positive malignancies, including 90% of pancreatic, 45% of colon, and 35% of lung cancers.

Today, we congratulate Tosk, Inc. for winning this years annual Stellar Business Award for Pharmaceutical Discovery and Development in Global. Our selection committee reviewed several outstanding companies for this award, and we decided unanimously that they are the official winners.

Competition in Pharmaceutical Discovery and Development

– OncoGenex Pharmaceuticals
– ArQule
– Merrimack Pharmaceuticals
– Blueprint Medicines
– Deciphera Pharmaceuticals
– Karyopharm Therapeutics
– Syros Pharmaceuticals
– Verastem Oncology
– X4 Pharmaceuticals
– Zafgen

Tosk, Inc. Reviews

Our team at Stellar Business reviews companies based on several factors, including online reviews, the ability to deliver results, interactions with leadership, and more. Based on these metrics, we then create a weighted overall score.

When giving reviews, we interviewed Brian Frenzel about their success in the Global area. We also looked at what their customers were saying on Google and other trusted review sites. Because Tosk, Inc. maintains consistently stellar reviews, they received strong consideration for this award.

Best Business Consulting in Global

Tosk, Inc. quickly became our strongest applicants in Global. They displayed excellent customer service, an ability to deliver, and maintain high reviews in their community. So, Stellar Business would like to endorse them as the top Pharmaceutical Discovery and Development in Global. We believe that their outstanding ability to serve their clients in Global makes them a long-time favorite provider.

Brian Frenzel Recognized as President of Tosk, Inc.

Mr. Frenzel is an experienced life science company executive and entrepreneur. He also serves as a Senior Advisor, and formerly a Board member, of SanBio Ltd (TSE:4592), a cell therapy company focusing on neurodegenerative diseases. His previous management experience includes co-founding and serving as the CEO of Centaur Pharmaceuticals, a neurodegenerative disease pharmaceutical company (acquired by Renovis, NASDAQ:RNVS), Vesta Medical, a medical device company (acquired by Pfizer, NYSE:PFE), Adeza Biomedical, a specialty diagnostics company (NASDAQ:ADZA, acquired by Cytyc, NASDAQ:CYTC), and co-founding and serving as COO/CFO of Genelabs Technologies, a biotechnology company (NASDAQ:GNLB).

Prior to entering the startup company arena, Mr. Frenzel was the Director of Corporate Planning at Syntex Corporation, then the largest West Coast life science company, a Principal at Booz, Allen & Hamilton, a Consultant at the Boston Consulting Group, and a Lieutenant in the United States Navy Nuclear Power Program. Mr. Frenzel holds a BS in physics and an MBA from Stanford University.

Best Business Consulting in Global

To confirm them as the official winner of our Stellar Business Award for excellence in {text:39} in Global, we made the following announcements:

  • This public post on our website highlights them as the winner

  • A public announcement on our LinkedIn, Instagram, and Facebook page 

  • Provided a physical certificate signed by our committee

  • Assured that there are no other winners for the category of Pharmaceutical Discovery and Development in Global

  • Sent a physical Stellar Business trophy to symbolize this award

We encourage you to visit our award winner’s business website to learn more about how they can help you with Pharmaceutical Discovery and Development in Global. Link below.

Contact: Brian Frenzel

Stellar Business